drugset / Trial / NCT06364917
DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC
RandomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study, known as DISCERN, is to compare two different treatments for a type of lung cancer called non-small cell lung cancer (NSCLC) that does not show a marker known as PD-L1. This study will help us understand if using two types of immune therapy together with chemotherapy is better than using one type of immune therapy with chemotherapy. We're doing this by looking at changes in the subject's cancer's DNA in the blood after starting treatment.
Timeline
- Start
- 2025-05-30
- Primary completion
- 2027-04-27
- Completion
- 2027-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 360 mg | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Carboplatin | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | 200 mg/m2 | — |
| Background | Pemetrexed | Small molecule | 500 mg/m2 | — |